Redeye comments on Lipigon’s Q4 report 2025. In Q4, Lipigon presented inconclusive results in its phase II study of Lipisense. Additional analyses have shown positive effects on glucose and ApoB-48. The cash runway is now likely a few more months and we believe the company needs a partner to survive.
LÄS MER
